H. Lundbeck A — Share Issue/Capital Change 2016

Feb 23, 2016

Valby, Denmark, 2016-02-23 11:54 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 23
February 2016 - H. Lundbeck A/S (Lundbeck) today announced that it has decided
to increase its share capital by DKK 200,520, as a consequence of the exercise
of employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 5: 13,435 shares at DKK 115, 3,897
shares at DKK 102, 2,326 shares at DKK 97, 8,662 shares at DKK 121 and 11,784
shares at DKK 113. Proceeds to the company are DKK 4,547,835 (approximately USD
672,001). The increase corresponds to approximately 0.0203 % of the company's
share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company from the time of
registration of the capital increase. The new shares will be listed on NASDAQ
OMX Copenhagen after registration with the Danish Business Authority.
Lundbeck's current share capital amounts to DKK 986,506,405 and will after the
capital increase be DKK 986,706,925. The capital increase is expected to be
finalized shortly.

Lundbeck contacts

Investors: Media:

Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Director, Corporate Communication
PALO@lundbeck.com MAVK@lundbeck.com
+45 36 43 24 26 +45 36 43 30 00

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in psychiatric and neurological disorders. For more than 70 years,
we have been at the forefront of research within neuroscience. Our key areas of
focus are depression, schizophrenia, Parkinson's disease and Alzheimer's
disease.

An estimated 700 million people worldwide are living with psychiatric and
neurological disorders and far too many suffer due to inadequate treatment,
discrimination, a reduced number of working days, early retirement and other
unnecessary consequences. Every day, we strive for improved treatment and a
better life for people living with psychiatric and neurological disorders – we
call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,300 employees in 55 countries are engaged in the entire
value chain throughout research, development, manufacturing, marketing and
sales. Our pipeline consists of several late-stage development programmes and
our products are available in more than 100 countries. We have research centres
in China and Denmark and production facilities in China, Denmark, France and
Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion;
USD 2.2 billion).

For additional information, we encourage you to visit our corporate site
www.lundbeck.com and connect with us on Twitter at @Lundbeck.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our
expectations or forecasts of future events such as new product introductions,
product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions. This may cause actual results to differ materially from
expectations and it may cause any or all of our forward-looking statements here
or in other publications to be wrong. Factors that may affect future results
include interest rate and currency exchange rate fluctuations, delay or failure
of development projects, production problems, unexpected contract breaches or
terminations, government-mandated or market-driven price decreases for
Lundbeck's products, introduction of competing products, Lundbeck's ability to
successfully market both new and existing products, exposure to product
liability and other lawsuits, changes in reimbursement rules and governmental
laws and related interpretation thereof, and unexpected growth in costs and
expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for
full disclosure of material corporate information. Some assumptions, including
assumptions relating to sales associated with product that is prescribed for
unapproved uses, are made taking into account past performances of other
similar drugs for similar disease states or past performance of the same drug
in other regions where the product is currently marketed. It is important to
note that although physicians may, as part of their freedom to practice
medicine in the US, prescribe approved drugs for any use they deem appropriate,
including unapproved uses, at Lundbeck, promotion of unapproved uses is
strictly prohibited.